Regulatory function of interferon‐inducible 44‐like for hepatitis B virus covalently closed circular DNA in primary human hepatocytes
Regulatory function of interferon‐inducible 44‐like for hepatitis B virus covalently closed circular DNA in primary human hepatocytes
复制标题
干扰素诱导型44样蛋白对原代人肝细胞中乙型肝炎病毒共价闭合环状DNA的调节功能
DOI:
10.1111/hepr.13722
复制
发表时间:
2021
影响因子:
4.2
通讯作者:
Nakamoto Yasunari
中科院分区:
文献类型:
--
作者:
Nosaka Takuto;Naito Tatsushi;Murata Yosuke;Matsuda Hidetaka;Ohtani Masahiro;Hiramatsu Katsushi;Nishizawa Tsutomu;Okamoto Hiroaki;Nakamoto Yasunari
AimCuring hepatitis B virus (HBV) infection requires elimination of covalently closed circular DNA (cccDNA). Interferon (IFN)‐γ has noncytolytic antiviral potential; however, elimination of cccDNA could not be achieved. To enhance the regulatory effect, we comprehensively analyzed the host factors associated with cccDNA amplification and IFN‐γ and IFN‐α effects using an in vitro HBV infection system showing various transcription levels.MethodsPrimary human hepatocytes were infected with HBV using genomic plasmids carrying the basic core promoter mutation A1762T/G1764A and/or the precore mutation G1896A and treated with IFN‐γ and IFN‐α. Comprehensive and functional studies involving microarray and small interfering RNA analysis revealed the host factors related to cccDNA regulation.ResultsThe HBV infection system reproduced the HBV life cycle and showed various propagation levels. Microarray analysis revealed 53 genes correlated with the cccDNA levels. Of the 53 genes, expression of IFN‐induced protein 44‐like (IFI44L) was significantly upregulated by IFN‐γ and IFN‐α. The anti‐HBV effect of IFI44L is exerted regardless of IFN‐γ or IFN‐α by inhibiting the activation of nuclear factor‐κB and signal transducer and activator of transcription 1 pathways.ConclusionsUsing the in vitro HBV infection system, an IFN‐inducible molecule, IFI44L, associated with cccDNA amplification, was identified. These results suggest an innovative molecular strategy for the regulation of HBV cccDNA by controlling a novel host factor, IFI44L.